Paladin Labs, the Canadian speciality pharmaceutical company, is expanding its reach into the sub-Saharan pharmaceuticals market by acquiring all the Pharmaplan shares it does not already hold and then merging the business with the pharma assets of Litha Healthcare, to become its largest shareholder with a 44.5% stake. The series of transactions will cost Paladin some Can$52 million.
Paladin expands African roots with Litha partnership
Paladin Labs, the Canadian speciality pharmaceutical company, is expanding its reach into the sub-Saharan pharmaceuticals market by acquiring all the Pharmaplan shares it does not already hold and then merging the business with the pharma assets of Litha Healthcare, to become its largest shareholder with a 44.5% stake. The series of transactions will cost Paladin some Can$52 million.
More from Archive
• By
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
• By
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
• By
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
• By
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
More from Scrip
• By
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.
• By
The company closed a $150m series C funding round shortly after opening the second part of its Phase I/II study of ATSN-201 and partnering with a Nippon Shinyaku on ATSN-101.
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.